AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
Finerenone is a promising therapy for HFpEF/HFmrEF, particularly in patients with the cardiovascular-kidney-metabolic syndrome (CKM).
Mineralocorticoid receptor antagonists (MRAs) are a central component of contemporary cardiorenal protection in chronic kidney disease (CKD). Classic steroidal MRAs, spironolactone and eplerenone, have long been used to treat hypertension and heart failure and to reduce albuminuria, but their wider use in CKD has been...
BACKGROUND Finerenone, a non-steroidal mineralocorticoid receptor antagonist, improves cardiorenal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. However, real-world data on its use in patients with concomitant heart failure remain limited. This study aimed to evaluate the baseline chara...
BACKGROUND Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces risk of heart and kidney outcomes in people with chronic kidney disease (CKD) and type 2 diabetes (T2D). Heart failure is the leading cause of hospitalization in patients with CKD. Here we evaluated whether the reduction in estimated g...
Heart failure (HF) with preserved ejection fraction (HFpEF) is a major clinical difficulty caused by the existence of restricted therapeutic alternatives. Sodium-glucose cotransporter-2 inhibitors, including dapagliflozin, have demonstrated possible benefits in the therapy of HF. A randomized controlled...
Abstract: Mineralocorticoid receptor activation contributes to cardiovascular and kidney injury through inflammation, fibrosis, oxidative stress, endothelial dysfunction, and adverse tissue remodeling. Eplerenone, a selective steroidal mineralocorticoid receptor antagonist (MRA) developed to minimize the endocrine adve...
Mineralocorticoid receptor antagonists (MRAs) are a well-established treatment option for the management of heart failure (HF) with reduced ejection fraction. However, high-quality evidence for the effect of MRAs in the treatment of heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) has bee...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.